Rutherford Diagnostics

Proton Partners International is one of the UKs most technologically advanced and rapidly growing businesses, operating four subsidiary companies; Rutherford Diagnostics, Rutherford Cancer Centres, Rutherford Innovations and Rutherford Estates.

Rutherford Cancer Centres have pioneered the use of proton therapy in the UK and in just three years have developed the world’s largest network of proton therapy centres, with another set to open in Liverpool in 2019.

The city will also become home to Rutherford Diagnostics’ first large scale imaging centre. This six-storey facility will bring additional MRI, PETCT and CT capacity to the city, in addition to pioneering the use of new imaging modalities. The first of an initial five centres, the Liverpool facility will also boast the latest in genomic sequencing technology which will put the city at the global heart of this revolutionary technology.

Rutherford Innovations leads the research and development activities for the Rutherford companies. With its mission statement of ‘Vision to Value’, Rutherford Innovations seeks innovative technologies and processes to unlock new value for the Rutherford companies through its focus on delivering better patient outcomes.

Rutherford Estates leads the development and build of each of the pioneering facilities operated by the Rutherford group of companies. Recognised internationally for its ability to deliver complex projects with exceptional attention to detail, the company has become a world leader in the construction of cutting edge healthcare facilities.